← Back to patent-cliff list
Lopinavir/Ritonavir/Lamivudine/Zidovudine
Tier C — Watch / tradeLopinavir/Ritonavir/Lamivudine/Zidovudine
Cipla Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HIV-1 RT, HIV-1 protease, RT
Indications (approved)：HIV infection
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lopinavir/Ritonavir/Lamivudine/Zidovudine?
Approved indications include: HIV infection.
When does the Lopinavir/Ritonavir/Lamivudine/Zidovudine patent expire?
No public expiry year is available for Lopinavir/Ritonavir/Lamivudine/Zidovudine yet; this page updates once verified.
How do I get a quote for Lopinavir/Ritonavir/Lamivudine/Zidovudine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08